Robert J Kinders

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, NationalCancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 16:5447-57. 2010
  2. ncbi request reprint Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations
    Robert Kinders
    Authors Affiliations Laboratory of Human Toxicology and Pharmacology National Cancer Target Validation Laboratory, Applied Developmental Research Directorate, Frederick National Laboratory for Cancer Research and Leidos Biomedical Research, Inc, Frederick, Maryland
    Clin Cancer Res 20:2578-86. 2014
  3. pmc Advances in using PARP inhibitors to treat cancer
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med 10:25. 2012
  4. pmc Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 14:6877-85. 2008
  5. pmc Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues
    Thomas D Pfister
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
    PLoS ONE 7:e50494. 2012
  6. pmc Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells
    Lihua H Wang
    Laboratory of Human Toxicology and Pharmacology, Science Applications International Corporation, Frederick, MD, USA
    Clin Cancer Res 16:1073-84. 2010
  7. pmc Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells
    JIUPING JI
    National Clinical Target Validation Laboratory, National Cancer Institute at Frederick, Frederick, Maryland, United States of America
    PLoS ONE 6:e26152. 2011
  8. pmc Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    Annamaria Rapisarda
    SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1867-77. 2009
  9. pmc Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
    Thomas D Pfister
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1878-84. 2009

Collaborators

Detail Information

Publications9

  1. pmc Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, NationalCancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 16:5447-57. 2010
    ..A quantitative pharmacodynamic immunofluorescence assay for γH2AX was developed, validated, and tested in human tumor xenograft models with the use of clinically relevant procedures...
  2. ncbi request reprint Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations
    Robert Kinders
    Authors Affiliations Laboratory of Human Toxicology and Pharmacology National Cancer Target Validation Laboratory, Applied Developmental Research Directorate, Frederick National Laboratory for Cancer Research and Leidos Biomedical Research, Inc, Frederick, Maryland
    Clin Cancer Res 20:2578-86. 2014
    ..SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "PROGRESS IN PHARMACODYNAMIC ENDPOINTS": Clin Cancer Res; 20(10); 2578-86. ©2014 AACR. ..
  3. pmc Advances in using PARP inhibitors to treat cancer
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, 31 Center Drive, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Med 10:25. 2012
    ....
  4. pmc Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 14:6877-85. 2008
    ..S. Food and Drug Administration's Exploratory Investigational New Drug Application. Performance of the study design, needle biopsy procedure, and validated pharmacodynamic assay were evaluated in human tumor xenograft models...
  5. pmc Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues
    Thomas D Pfister
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, SAIC Frederick, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
    PLoS ONE 7:e50494. 2012
    ..Cellular response to Top1 inhibitors is complex, but Top1 target engagement is a necessary first step in this process. This paper reports the development and validation of a quantitative immunoassay for Top1 in tumors...
  6. pmc Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells
    Lihua H Wang
    Laboratory of Human Toxicology and Pharmacology, Science Applications International Corporation, Frederick, MD, USA
    Clin Cancer Res 16:1073-84. 2010
    ..Here, we describe an assay that directly examines changes in levels of the nuclear DNA damage marker gammaH2AX in individual CTCs of patients treated with chemotherapeutic agents...
  7. pmc Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells
    JIUPING JI
    National Clinical Target Validation Laboratory, National Cancer Institute at Frederick, Frederick, Maryland, United States of America
    PLoS ONE 6:e26152. 2011
    ....
  8. pmc Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    Annamaria Rapisarda
    SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1867-77. 2009
    ..These results strongly suggest that combination of anti-vascular endothelial growth factor antibodies with HIF-1 inhibitors is an attractive therapeutic strategy targeting in the hypoxic tumor microenvironment...
  9. pmc Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
    Thomas D Pfister
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1878-84. 2009
    ....